A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors

被引：2

作者：

Arkenau, Hendrik-Tobias

Gazzah, Anas

Plummer, Ruth

Blagden, Sarah Patricia

Mak, Gabriel

Soria, Jean-Charles

Greystoke, Alastair

Rizzuto, Ivana

Rogan, Debra

Mazumdar, Jolly

Laubscher, Kevin

Auger, Kurt R.

Swartz, Lisa S.

Mattern, Maria L.

Nebot, Noelia

Singh, Rajendra P.

Fleming, Ronald Alan

Yan, Li

机构：

[1] Sarah Cannon Res United Kingdom, London, England

[2] Inst Gustave Roussy, Drug Dev Dept DITEP, Villejuif, France

[3] Newcastle Univ, Northern Inst Canc Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England

[4] Ovarian Canc Act Res Ctr, London, England

[5] Sarah Cannon Res Inst UK, London, England

[6] Drug Dev Dept, Villejuif, France

[7] Freeman Rd Hosp, Northern Ctr Canc Care, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England

[8] NIHR Wellcome Trust Imperial Clin Res Facil, London, England

[9] GlaxoSmithKline, Res Triangle Pk, NC USA

[10] GlaxoSmithKline, Collegeville, PA USA

[11] GlaxoSmithKline Rsrch & Dev, Res Triangle Pk, NC USA

来源：

关键词：

D O I：

10.1200/jco.2015.33.15_suppl.2593

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2593

引用

页数：1